Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02573766 · ClinicalTrials.gov registry record · NA
Neuromodulation as a Treatment for Chemotherapy-Induced Peripheral Neuropathy
A NA study of Pain, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 91
- Enrollment target
- 1
- Study location
NCT02573766: Active NA study of Pain, sponsored by M.D. Anderson Cancer Center.
NCT02573766 is a NA study of Pain that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 91 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02573766, a NA study of Pain, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 91 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if using a type of non-invasive therapy called neurofeedback training can help teach patients with peripheral neuropathy how to change their own brain waves to lower their perception of neuropathy and help improve their overall quality of life. Neurofeedback training is a type of therapy that uses an electroencephalograph (EEG) and a computer software program to measure brain wave activity. This is an investigational study. The equipment used for neurofeedback training is FDA approved and commercially available. Using neurofeedback equipment to teach patients ways to modify their own brain waves to lower the perception of symptoms and improve quality of life is considered investigational. Up to 99 participants over the age of 18 will take part in this study. All will be enrolled at MD Anderson.
Primary Outcome
Pain Quality Assessment Scale (PQAS) used to evaluate responses in each group.
Conditions Studied
Interventions
- BEHAVIORAL Questionnaires
- PROCEDURE Neurofeedback Training
- PROCEDURE Electroencephalogram
- BEHAVIORAL Pain Scale
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2015-10-01 |
| Est. Completion | 2026-10-01 |
| Phase | NA |
What the registry record for NCT02573766 still lists
NCT02573766 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 4 interventions - of which Questionnaires is the first listed.
NCT02573766 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02573766 about?
NCT02573766 is a clinical study titled "Neuromodulation as a Treatment for Chemotherapy-Induced Peripheral Neuropathy". The goal of this clinical research study is to learn if using a type of non-invasive therapy called neurofeedback training can help teach patients with peripheral neuropathy how to change their own brain waves to lower their perception of neuropathy and help improve their overall quality of life. N...
What is the current status of trial NCT02573766?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 91 participants. The study started on 2015-10-01. Estimated completion is 2026-10-01.
What conditions does trial NCT02573766 study?
This clinical trial studies the following conditions: Pain.
What interventions are being tested in trial NCT02573766?
The interventions under investigation include: Questionnaires (BEHAVIORAL), Neurofeedback Training (PROCEDURE), Electroencephalogram (PROCEDURE), Pain Scale (BEHAVIORAL).
Who is sponsoring clinical trial NCT02573766?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02573766 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02573766's enrollment target sits among peer trials
91 181st of 374 higher than 194 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Postoperative Pain After Activation of Irrigant
RECRUITING · NA
-
Neural Mechanisms of Immersive Virtual Reality in Chronic Pain (VR TMD EEG)
RECRUITING · NA
-
Pain With Dementia
RECRUITING · NA
-
Oklahoma Study of Native American Pain Risk IV: Smoking Cessation and Pain
RECRUITING · NA
-
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
RECRUITING · NA
-
TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI